SDMHF:OTC-Sartorius Stedim Biotech S.A (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 200.89

Change

0.00 (0.00)%

Market Cap

USD 20.59B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-30 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

-0.58 (-0.50%)

USD 109.05B
ESLOF EssilorLuxottica Société ano..

-1.38 (-0.60%)

USD 107.93B
HOCPF HOYA Corporation

N/A

USD 48.46B
HOCPY Hoya Corp

+2.25 (+1.71%)

USD 45.95B
CLPBF Coloplast A/S

N/A

USD 29.48B
CLPBY Coloplast A

-0.28 (-2.14%)

USD 29.48B
TRUMF Terumo Corporation

+0.11 (+0.60%)

USD 28.34B
SAUHF Straumann Holding AG

-3.14 (-2.38%)

USD 24.34B
OCPNF Olympus Corporation

N/A

USD 21.42B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 20.59B

ETFs Containing SDMHF

RNDM 1.76 % 0.65 %

N/A

N/A
SCIX 1.04 % 0.38 %

N/A

N/A
KIE SPDR® S&P Insurance ETF 0.00 % 0.35 %

+0.28 (+-0.63%)

N/A
DJMC:LSE iShares EURO STOXX Mid UC.. 0.00 % 0.00 %

-35.00 (-0.63%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.83% 55% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.83% 55% F 33% F
Trailing 12 Months  
Capital Gain 8.62% 57% F 54% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.62% 57% F 54% F
Trailing 5 Years  
Capital Gain 40.77% 85% B 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 40.77% 85% B 75% C
Average Annual (5 Year Horizon)  
Capital Gain 11.66% 61% D- 55% F
Dividend Return 11.91% 58% F 52% F
Total Return 0.25% 18% F 8% B-
Risk Return Profile  
Volatility (Standard Deviation) 58.43% 40% F 46% F
Risk Adjusted Return 20.39% 61% D- 55% F
Market Capitalization 20.59B 81% B- 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.